A recent study suggests that adding rituximab to a high‐dose methotrexate‐based combination chemotherapy could prolong overall survival as well as progression-free survival for patients with primary central nervous system lymphoma, a rare and aggressive form of lymphoma.
A recent study suggests that adding rituximab to a high‐dose methotrexate (HD‐MTX)‐based combination chemotherapy could prolong overall survival (OS) as well as progression-free survival (PFS) for patients with primary central nervous system lymphoma (PCNSL), a rare and aggressive form of lymphoma.
Since 2000, the preferred front‐line treatment for PCNSL has been HD‐MTX, with or without whole‐brain radiotherapy (WBRT), although there is no consensus about the most effective chemotherapy regimen. More frequently, however, rituximab plus combination chemotherapy is being used for these patients, who generally have poor outcomes.
To evaluate the survival benefit of adding rituximab, researchers searched the electronic databases, MEDLINE, EMBASE, COCHRANE, Web of Science, and SCOPUS to retrieve clinical studies; a total of 5 articles were included. Two of them were used to conduct qualitative meta‐analysis. Hazards ratios (HRs) with 95% confidence intervals (CIs) were pooled across studies using a random‐effects model.
The studies compared the OS between rituximab group and the control group. The OS was reported by median months of PFS, HR with 95% CI, or percent of OS for 2 years.
Three of the 5 studies reported overall OS by median month, in which OS was longer in the group with added rituximab than in the control group.
The other 2 studies presented OS as HR with 95% CI; the HRs between the rituximab group and the control group were 0.63 (95% CI, 0.42‐1.02), and 0.73 (95% CI, 0.35‐1.52). The risk of heterogeneity was very low between the 2 studies (Q‐value = .859, P = .354; I2 = 0.000). When the 2 studies were combined with a fixed effect model, the pooling estimate of HR was 0.604 with 95% CI of 0.413 to 0.883 (P <.01).
The meta‐analysis on PFS suggests that there was no significant heterogeneity between the studies, the authors said.
Reference
Lee W, Go S, Kwon O. The role of rituximab in primary central nervous system lymphoma (PCNSL): A systematic review and meta‐analysis. Presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, June 18-22, 2019; Lugano, Switzerland. Abstract 424.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment
December 9th 2024The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.